Analysis of the soluble receptor distribution revealed a preferential expression in lung, liver, pancreas and placenta. sOSMR was able to bind OSM and IL-31 when associated to soluble gp130 or soluble IL-31R respectively, and to neutralize both cytokine properties. We also show that OSM could positively regulate the synthesis of its own soluble receptor in tumor cells.
Activation of the signaling transduction pathways mediated by oncostatin M (OSM) requires the binding of the cytokine to either type I OSM receptor (LIFR / gp130) or to type II OSM receptor (OSMR / gp130
). In the present work we have developed an ELISA detecting a soluble form of OSMR (sOSMR) secreted by glioblastoma, hepatoma and melanoma tumor cell lines. sOSMR was also present in sera of healthy individuals, with increased levels in multiple myeloma. Molecular cloning of a corresponding cDNA was carried out and it encoded for a 70 kDa protein consisting of a half cytokine binding domain containing the canonical WSXWS motif, an immunoglobulin-like domain and the first half of a second cytokine binding domain with cysteines in fixed positions. Analysis of the soluble receptor distribution revealed a preferential expression in lung, liver, pancreas and placenta. sOSMR was able to bind OSM and IL-31 when associated to soluble gp130 or soluble IL-31R respectively, and to neutralize both cytokine properties. We also show that OSM could positively regulate the synthesis of its own soluble receptor in tumor cells.
OSM was originally isolated from culture supernatant of U937 histiocytic leukemia cells based on its ability to inhibit the proliferation of the A375 melanoma cell line (1, 2) . OSM is produced by activated monocytes, T lymphocytes and dendritic cells, cell types and is also described as a potent inducer of inflammation (3) (4) (5) (6) (7) (8) . OSM belongs to the interleukin-6 cytokine family also encompassing IL-11, IL-27, leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), cardiotrophin-1, cardiotrophin-like cytokine and neuropoietin (9) (10) (11) (12) .
The cytokines of the IL-6 family use two or three membrane subunit receptors to form high affinity receptor complexes able to mediate downstream signaling events (13) (14) . These receptors belong to the type I cytokine receptors, characterized by the presence of at least one cytokine binding domain (CBD) with conserved cysteine positions and a WSXWS motif (15) . All the receptor complexes belonging to the IL-6 cytokine family share the common gp130 signaling receptor subunit in the formation of their multimeric receptors (16) . Depending on the ligand, gp130 can either homo-dimerize in the presence of IL-6 or IL-11 (17,18), or heterodimerize with related type I cytokine receptors, such as LIFR, IL-27R or OSMR, when recruited by other members of the IL-6 family of cytokines (19) (20) (21) .
In humans, OSM signal transduction occurs via two distinct receptor complexes. The type I OSM receptor consists of the low affinity chain, LIFR, associated to gp130 (19) . This type I receptor can indifferently bind LIF or OSM. Through this mechanism, OSM elicits biological activities overlapping with those induced by LIF, such as hepatocyte activation, bone renewal, or the in vitro maintenance of ES cell phenotype (22) .
The type II OSM receptor, specifically recognizing OSM, associates gp130 and the OSMR subunit (23) . OSMR is a 150 kDa protein composed in its external portion of a half CBD followed by an immunoglobulin-like domain, a second complete CBD and then a region consisting of three FnIII domain repeats. The cytoplasmic domain of the receptor contains motives required for the recruitment of Jak1, Jak2, Tyk2 as well as of STAT1, STAT3 and STAT5 signaling pathways (24, 25) .
The interaction of OSM with its specific type II receptor mediates OSM's unique functions that can not be mimicked by LIF or other IL-6 family members. Signaling by the type II OSM receptor inhibits the proliferation of a number of tumor cells, including glioblastoma, melanoma, mammary and prostatic cell lines (1, 2, (26) (27) (28) . In addition, OSM potently induces the proliferation of Kaposi's sarcoma, fibroblastic and smooth muscle cells (29) (30) (31) .
It was recently reported, that OSMR could also be recruited by IL-31, a novel cytokine with a skin tropism (32) (33) (34) .
Soluble cytokine receptors are involved in the regulation of a number of physiological and pathological situations. They can either behave as agonists or antagonists of cytokine signaling depending on the particular family of cytokines. Soluble cytokine receptors can be generated by different mechanisms, including proteolytic cleavages of the receptor extracellular parts, alternative splicing of RNA transcripts or by cleavage of a glycosyl-phosphatidyl-inositol anchor (35) .
The soluble counterparts of alpha-membrane chains, such as soluble IL-6 or CNTF receptors, are able to potentiate the functional responses to their respective ligands (36, 37) . In contrast, betachain derived soluble receptors, such as soluble gp130, neutralize the response to IL-6, IL-11 or CNTF (38) . In the present work we have molecularly and functionally characterized a soluble form of the OSM / IL-31 shared receptor.
MATERIALS AND METHODS
Cells and reagents -All the cell lines used in this study were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum. BA/F3 gp130/OSMR and BA/F3 gp130/LIFR factor dependent cell lines were grown in the same culture medium supplemented with OSM and LIF, respectively, as previously described (39) . Human OSM, IFNγ, TGFβ, IL-1α, IL-2, IL-10, IL-11, CT-1, soluble CNTF receptor (sCNTFR), soluble gp130 (sgp130), soluble LIF receptor (sLIFR), soluble IL-6 receptor (sIL-6R), soluble IL-4 receptor (sIL-4R) were purchased from R&D Systems (Oxon, UK). Drosophila Toll-Fc, human CLF-Fc, GPL/IL-31R-Fc and IL-31 were made in the laboratory as previously described (11, 34, 40) . Antibody raised against phospho-STAT3 was bought from Upstate Biotechnology (Lake Placid, NY). Anti-STAT3 antibody was from Santa Cruz Biotechnology (Santa Cruz, CA). The anti-V5 antibody coupled to peroxidase was purchased from Invitrogen (Carlsbad, CA). Goat anti-mouse and anti-rabbit peroxidase labeled immunoglobulins were from Clinisciences (Montrouge, France). Monoclonal antibodies against gp130 (AN-G73, AN-G40) were produced in the laboratory. Anti-OSMR antibodies (described in figure 1) were obtained following the conventional protocols after immunization of the mice with a soluble form of OSMR and by fusing the splenocytes with the SP2/o myeloma.
Serum samples -Sera from healthy humans were obtained from informed volunteers, and the sera of multiple myeloma-suffering patients were obtained from people who gave their informed consent in agreement with the French legislation.
ELISA detection -For the detection of the soluble forms of OSMR and gp130, the AN-A2 (anti-OSMR) or AN-G73 (anti-gp130) mAbs were coated at a concentration of 10 µg/ml in 50 mM carbonate buffer pH 9.6. After washes and a Tris 0.1M Sucrose 20% saturation step, the samples were incubated overnight at 4°C. The detection was performed using 1 µg/ml AN-V2 (anti-OSMR) or AN-G40 (anti-gp130) biotinylated mAbs in PBS BSA 0.1% tween 0.01%, followed by a steptavidin peroxidase step. Visualization was performed using ABTS as substrate and the reading performed at 405.
Cloning of sOSMR spliced form -Total RNAs from WRL68 hepatoma cell line were extracted by the TRIzol method according to the manufacturer's instructions (Invitrogen, Cergy Pontoise, France). cDNA was amplified with the Advantage polymerase (Clontech, Palo Alto, CA) using 10 nM OSMR sense primer CGGCCTGCCTACCTGAAAAC and an oligo dT primer (Invitrogen). PCR products were cloned in the pGEMT vector (Promega) and the sequencing was performed using an automatic DNA sequencer (Beckman Coulter). To express the recombinant sOSMR, the 3' end of the cDNA was replaced by a V5-His tag and subcloned in the pcDNA3.1D/ TOPO-V5-His mammalian expression vector (Invitrogen).
Protein expression and purification -The HEK 293 cell line was stably transfected with sOSMR-V5-His pcDNA3.1D/TOPO plasmid using the Exgen transfection reagent (Euromedex, Souffelweyersheim, France). Cell supernatants were submitted to an anion exchange column (Amersham Biosciences,) before an affinity purification step using a Ni2+ sepharose column chromatography (Amersham, Biosciences,). Purified fractions were desalted by size exclusion before being submitted to SDS/PAGE silver staining and Western blotting analyses. The OSMR-Fc was a fusion protein made of the extracellular part of the membrane receptor coupled to the Fc portion of human IgG1 (34) . In figure 8B and 9E a fusion protein consisting of the first 428 residues of sOSMR fused to a 40-residue linker and to the Ig domain of gp130 (amino acids 767-817) was used. The Fc and fusion proteins were expressed in COS and HEK 293 cell lines, respectively. The culture supernatants were collected and loaded either on a protein A-sepharose or on a Ni2+ sepharose column, and the recombinant proteins eluted. Purity and protein determination analyses were carried out by SDS-PAGE and by silver staining.
RT-PCR analyses -cDNAs were synthesized from 2 µg of total RNA by random hexamer primers using MMLV reverse transcriptase (Promega, Madison, WI). Reverse transcription products were subsequently amplified by 35 cycles of PCR using the following primers: for sOSMR (sense TCTGGGGAAAAGAAACTTTGTAC, antisense TAAGCAGGGTTCTTACTTGC), by 25 cycles of PCR using the primers for OSMR (sense TCTGGGGAAAAGAAACTTTGTAC, anti-sense GTACTCGCGCCATGTACTCT) and by 20 cycles of PCR using the primers for GAPDH (sense ACCACAGTCCATGCCATCAC, anti-sense TCCACCACCCTGTTGCTGTA). Amplified products were analyzed by 2% agarose gel electrophoresis.
Real time quantitative PCR -Quantitative RT-PCR was carried out using the LightCyclerFastStart DNA MasterPLUS SYBR Green I kit (Roche, Mannheim, Germany). The cDNA tissue samples were obtained from Clontech. The reaction components were 1X FastStart DNA MasterPLUS SYBR Green I and 5 nM of the forward and reverse primers for sOSMR (forward CCTTTTTAACCTGACTCATCG, reverse AGCAGGGTTCTTACTTGCAT), for OSMR (forward AGATTGAACTCCATGGTGAA, reverse GCTTCAAGTGTGGTGAAGTT) and for GAPDH (forward GAAGGTGAAGGTCGGAGTC, reverse GAAGATGGTGATGGGATTTC).
Data analysis was performed as indicated by Roche using the "Fit Point Method" in the Light Cycler software 3.3 (Roche Diagnostics). Quantification was made using the GAPDH as a house keeping gene.
Immunoprecipitation and Western blotting experiments -Cytokines and soluble receptors were preincubated at a final concentration of 5 nM each for 2 h at 37°C, before being added to the cells for 10 min. Cells were then lysed in SDS sample buffer, sonicated, submitted to SDS-PAGE and transferred onto an Immobilon membrane. The membranes were subsequently incubated overnight with the primary antibody before being incubated with the appropriate peroxidase-labelled secondary antibody for 1h. The reaction was visualized by ECL detection according to the manufacturer's instructions (Amersham Biosciences, Les Ullis, France). Membranes were stripped in 0.1 M glycine pH 2.8 for 2h before reblotting.
For the co-precipitation experiments, the cytokines were incubated at a concentration of 5 nM in the presence of the same concentration of soluble receptors. After an overnight contact, the proteins were precipitated using Ni2+ beads and analyzed by Western blotting, as described above.
Endoglycosidase treatment -The sOSMR receptor was diluted in 1% Brij 96 lysis buffer and treated with 25 units/mL of N-glycosidase-F (Roche, Mannheim, Germany) for 12 h at 37°C before Western blotting analysis.
Proliferation assays -Ba/F3 cell lines transfected with the appropriate cDNA receptors were seeded in 96 well plates at a concentration of 5 x 10 3 cells/well in RPMI 5% fetal calf serum (39) . Serial dilutions of tested cytokines or soluble receptors were performed in triplicate. After a 48 h incubation period, 0.5 µCi of 3 H thymidine was added to each well for the last 4 h of the culture and the incorporated radioactivity determined by scintillation counting (Packard Topcount luminometer, Meriden, CT). Flow Cytometry Analysis -Cells were incubated for 30 min at 4°C with the AN-N2 anti-OSMR antibody or an isotype control antibody (IgG1) (10 µg/ml), before an incubation step with a phycoerythrin conjugated anti-mouse antibody. Fluorescence was subsequently analyzed on a FACScalibur flow cytometer from Becton Dickinson (Mountain View, CA).
RESULTS

Detection of a soluble form of OSMR by
ELISA -Eighteen monoclonal antibodies recognizing the soluble OSMR part of an Fc fusion protein were generated and characterized. Each of them was tested in pairs to develop a sandwich ELISA ( Figure 1A) . We selected the AN-A2 anti-OSMR mAb as a coating antibody, and the AN-V2 anti-OSMR mAb as a tracer antibody. The ELISA allowed the detection of 2.5 ng/ml recombinant soluble OSMR ( Figure  1B) , and did not react with any other related soluble receptors (LIFR, gp130, CNTFR, CLF, IL-6R) or irrelevant receptors (soluble drosophila Toll, soluble human IL-4R) ( Figure  1C) . Moreover, addition of OSM to the samples did not interfere with the detection of soluble OSMR in the developed ELISA.
We next looked for a native form of sOSMR by screening culture supernatant from different cell lines. All the tested glioblastoma, hepatoma and melanoma cell lines secreted high amounts of a soluble form of OSMR with concentrations ranging from 5 to 50 ng/10 6 cells ( Figure 2 ). In contrast, we could not observe the secretion of sOSMR in neuroblastoma, choriocarcinoma and lymphocyte derived cell lines. In addition, high levels of sgp130 were also detected in the cell lines secreting sOSMR.
We also looked for sOSMR in sera from healthy individuals and from patients suffering of multiple myeloma, a pathology known to induce increased levels of circulating soluble cytokine receptors (41) . An average value of 77 ng/ml circulating sOSMR was measured in normal situation that reached a concentration of 288 ng/ml in multiple myeloma patients ( Figure  3 ). These results revealed the existence of a circulating form of OSMR that can be positively modulated in pathologic situations.
Molecular cloning and expression of a soluble
OSMR splice variant -The cloning of a soluble form of OSMR was carried out by RT-PCR starting from the WRL68 hepatoma cell line. A 1185 pb cDNA was isolated and encoded a truncated soluble form of OSMR of 394 amino acids diverging from the membrane form of OSMR by 16 amino acids encoded at the end of exon 8 ( Figure 4A-C) . The soluble receptor sequence included an N-terminal potential hydrophobic signal peptide (exon 1 and 2), a half CBD containing a WSXWS motif (exons 3 and 4), followed by an Ig like domain (exon 5), and then a half CBD presenting four conserved cysteine residues in fixed position (exons 6 to 7).
Soluble OSMR tissue distribution -Tissue distribution was analyzed by real-time quantitative RT-PCR using poly (A)+ RNA from different human tissues. Two pairs of primers were used, one specifically detecting the soluble form of receptor, and the second one only amplifying the membrane form of OSMR. The specificity of amplified products was controlled on a large panel of cell lines and tissues and in each case a single band corresponding to the expected molecular weight was observed on gels (data not shown). The soluble form of OSMR was expressed in pancreas, lung, liver, placenta and weakly in skeletal muscle ( Figure 5 ). With the exception of heart, preferentially expressing the membrane receptor, the distribution of both forms of OSM receptors was similar in the tested tissues.
Soluble OSMR expression and binding of OSM to sgp130 / sOSMR complex -
The sOSMR was expressed as a tagged protein (V5-histidine tags) and purified by affinity from culture supernatants of stably transfected cells ( Figure 6A ). SDS-PAGE gels and Western blotting analyses of the purified fraction evidenced a 75 kDa polypeptide, corresponding, after subtracting the tag molecular weight, to a mature protein of 70 kDa. Deglycosylation experiments were carried out using the Nglycosidase-F. A shift of 25 kDa was observed in agreement with the predicted occupation of 10 N-glycosylation sites. (Figure 6B ).
We next studied interaction between the OSM, sOSMR and sgp130 (Figure 7) . The soluble receptors were added to OSM or LIF, and the tagged sOSMR was precipitated using Ni2+ beads. The samples were assayed by Western blotting using an anti-OSM antibody to detect its association to sOSMR. The experiments show that OSM specifically recognized sOSMR, with a slight increase of the binding in the presence of sgp130.
Soluble OSMR neutralizes STAT3 signalingWe tested the possibility for sOSMR to behave as an antagonist for its ligands. Experiments were carried out using the GO-G-UVM and T98G glioblastoma, and A375 melanoma cell lines previously reported to be responsive to OSM ( Figure 8A) (1,28) . Treatment of the cells with OSM plus sgp130 showed a very slight or no decrease in STAT3 phosphorylation compared to the signal observed in the presence of OSM alone, in agreement with the published studies (42) . Importantly, the combined addition of both soluble receptors induced a marked decrease of STAT3 phosphorylation in the studied cell lines. This was not observed in the presence of LIF or IL-6, used as controls ( Figure  8B ). Recent studies have demonstrated the OSMR involvement, together with Gp130-like receptor (GPL), also known as IL-31R, in the formation of a functional IL-31 receptor complex (32) (33) (34) . We tested the possibility for sOSMR to also neutralize an IL-31 response in the T98G glioblastoma cell line ( Figure 8C ). Similarly to that observed for OSM, a decrease in STAT3 recruitment by IL-31 was observed when adding simultaneously sOSMR and soluble GPL/IL-31R to the cells.
Altogether, these results indicate that a combination of truncated OSMR and gp130, or GPL/IL-31R, could trap and neutralize OSM and IL-31 responses respectively.
Soluble OSMR combined to soluble gp130 neutralizes both type I and Type II OSM receptors -In the next experiment, murine IL-3 dependant BA/F3 cells engineered to specifically express type I (gp130 / LIFR) or type II (GP130 / OSMR) OSM receptors on their surface were used (39) . Both cell lines proliferated in a similar manner with the addition of OSM to the cultures ( Figure 9A,B) . A fifty percent inhibition of the signal was measured when sOSMR and sgp130 were added together to the type I or type II OSM receptor expressing BAF/3 cell cultures ( Figure  9C,D) . In contrast, no induced inhibition could be detected when type I receptor expressing cells were grown in the presence of LIF ( Figure 9E ). These experiments show that the interaction between OSM and sOSMR/sgp130 was sufficient to lower the functional signals mediated by either type I or type II OSM receptors.
OSM up-regulates its own soluble receptor -
We studied the possibility for tumor cells to modulate their sOSMR expression in response to OSM. Experiments were carried out using the A375 melanoma cell line and three glioblastoma cell lines. The expression levels of soluble and membrane forms of OSMR were first determined by RT-PCR ( Figure 10A) . A clear induction of the RNA coding for the soluble form of receptor was observed when treating A375, GO-G-UVM and U87MG cells with OSM. Importantly, no variation in the expression level of the membrane form of the receptor could be evidenced in any studied cell line, suggesting that OSM preferentially upregulated its soluble form of receptor ( Figure  10B and data not shown). Similar experiments were then performed at the protein level with the GO-G-UVM and A375 cell lines ( Figure 10C ). The obtained results showed an increased sOSMR secretion when the cells were grown in the presence of at least 12.5 ng/ml OSM.
Further experiments were carried out to test the possibility for additional gp130 signaling cytokines (IL-6, IL-11, LIF, CT-1), proinflammatory cytokines (IFNγ, IL-1α) or antiinflammatory mediators (dexamethasone, TGFβ, IL-10) to modulate the sOSMR secretion ( Figure  10D) . A positive modulation of sOSMR secretion was only observed in response to its cognate ligand.
Together these results demonstrate that OSM positively regulates the secretion of sOSMR, opening the possibility for tumor cells to display a reduce sensitivity to the static activity of the cytokine during an immune response.
DISCUSSION
In the present work we identified an alternatively spliced form of OSM receptor leading to the generation of a soluble form of receptor. Soluble type I cytokine receptors can be generated by different mechanisms including alternative splicing of mRNA transcripts and proteolytic shedding of receptor ectodomains. Cleavage of GPI-anchored receptor by phosphatidylinositol-specific phospholipase C was also reported in the case of CNTFR alpha chain (37) . Soluble IL-6 receptor is generated by two different ways: shedding of the external IL-6R portion or alternative splicing, resulting in the secretion of a soluble form of receptor that lacks the transmembrane domain (43) (44) (45) . Two large size signaling receptors belonging to the IL-6 family, gp130 and LIFR, have also been described as soluble products (38, 46) . In these latter cases the soluble receptors have been identified as splice variants of membrane forms. In the present work we highlight the existence of a soluble OSMR generated by alternative splicing in intron 8 leading to a stop codon after residue 394. In parallel experiments, we also explored the possibility for soluble OSMR to be simultaneously generated by shedding processes. Preliminary results show an induction of sOSMR, after a phorbol ester cell contact, which is counteracted by a metalloprotease inhibitor treatment (C.D., unpublished observations). This suggests that, in addition to the exon splicing mechanism, sOSMR can also be generated by proteolytic cleavage, similarly to that previously reported for the soluble IL-6R (43) (44) (45) .
The binding of soluble IL-6R/IL-6 complex to membrane gp130 confers an IL-6 signaling capability named "trans-signaling" (47) . This phenomenon is also reported for IL-11 or CNTF (37, 48) . In contrast, sgp130 or soluble LIFR abrogate the signaling mediated by the membrane form of receptors in response to the IL-6 family members (38, 46) . The present results show that sOSMR also behave as a neutralizing receptor for OSM.
The receptor transducing chains of the IL-6 family, gp130, LIFR and OSMR, have a modular organization containing in their ectodomain at least one Ig-like domain, a CBD and FnIII domains (49) (50) (51) . Structural analyses of this family of receptors revealed that high affinity binding of the cytokine to its receptor complex involves on one side the CBD of a first receptor subunit and on the other side the Ig-like domain of the second receptor component (50) (51) (52) (53) (54) . We previously reported that OSM binds to the CBD of gp130 and to the Ig-like domain of OSMR (52, 55) . In the soluble form of OSMR, the CBD located downstream from the Ig-like domain was truncated and stopped after half of the module-suggesting that this truncated portion of receptor is not able to bind a cytokine. The present work supports the idea that the Iglike domain of the soluble OSMR, that remains intact, contributes to its neutralizing potential.
Recent studies from Zymogenetics researchers and from our group reported that OSMR also associate to a gp130-like receptor, GPL or IL-31R, to generate a functional receptor for IL-31 (32) (33) (34) . In the present study we show that sOSMR together with GPL/IL-31R could also neutralize IL-31. Since the GPL/IL-31R receptor is devoid of Ig-like module and bind IL-31 trough its CBD, we can hypothesize that sOSMR on its side might also recognize IL-31 through its Ig-like domain. sOSMR circulating levels have been detected in healthy individuals with an average value of roughly 80 ng/ml, similarl to that reported for sgp130 (38) . Interestingly, a clear increase was observed in sera from multiple myelomasuffering patients, a pathology with an important inflammatory component. Analysis of circulating sOSMR in additional inflammatory or leukemia situations would bring further information about these diseases.
The results demonstrate that sOSMR requires the association with sgp130 to induce a potent neutralizing response. Interestingly, in tested tumor cell lines a co-expression of both forms of soluble receptors was observed, which was further increased in the presence of OSM. This opens the possibility for tumor cells to protect themselves against the static activities of OSM secreted by T lymphocytes and monocytes during the immune response. A similar process has already been described for Fas ligand. In this case lung and colon tumor cells inhibited Fas ligand-induced apoptosis by overproducing a decoy receptor (56) . A specific neutralization of sOSMR in tumor experimental models might improve the anti-tumoral response to OSM (57).
On the other hand, OSM has been demonstrated to induce severe inflammatory responses, notably by recruiting the hepatocytes. Recently, cytokines of IL-6 family were successfully neutralized either by using antibodies or by fused proteins encompassing truncated soluble receptors or by their association to immunoglobulin Fc fragmentsopening the possibility of new treatments in inflammatory pathologies (58) (59) (60) (61) . The development of a sOSMR -sgp130 association might also be useful to contribute to reduce the inflammatory response in acute or chronic diseases.
In conclusion, the present work identified a soluble form of OSMR that displays neutralizing properties towards OSM and IL-31, when associated to sgp130 or GPL/IL-31R respectively. Since OSMR or IL-31R gene inactivation only led to a mild decrease in platelet number or to an absence of phenotype in mice (32, 62) , the development of neutralizing strategies based on the use of sOSMR in chronic pathologies should bring useful reagents with potentially weak side effects.
.FIGURE 2. Detection of sOSMR and sgp130 in cell line supernatants. Culture media were collected after a 48 h period culture. The number of cells was determined by trypan blue dye exclusion. The sOSMR and sgp130 concentrations were determined by ELISA. A. OSM (5 ng/ml) was pre-incubated with sIL-4R, sgp130, sOSMR, or sgp130 and sOSMR (200 ng/ml each) for 2 h at 37°C. The GO-G-UVM glioblastoma and the A375 melanoma cell lines were stimulated with the studied proteins for 10 min, and the STAT3 tyrosine phosphorylation levels were determined. B. A fusion protein made of sOSMR linked to a gp130 soluble form neutralized specifically the OSM response. Cytokines (10 ng/ml) were pre-incubated with 100 ng/ml OSMR-L-gp130 for 2 h at 37°C. Pre-incubated samples, or cytokines alone, were added for 10 min to the GO-G-UVM glioblastoma cell line, and the STAT3 tyrosine phosphorylation levels were determined. C. IL-31 (10 ng/ml) was pre-incubated with soluble Fc tagged GPL (250 ng/ml), sOSMR (200 ng/ml), or a combination of both, for 2h before being added to the T98G, an IL-31 responsive glioblastoma cell line. After a 10-min contact, the STAT3 tyrosine phosphorylation levels were determined. Type II and type I receptor transfected BA/F3 cells were cultured in presence of 0.6 ng/ml OSM, 1.5 µg/ml sgp130 and 1.5 µg/ml sOSMR as indicated. E. 100 ng/ml OSMR-L-gp130 fused protein and 0.1 ng/ml OSM (in black) or 0.1 ng/ml LIF (in grey) were added to type I and type II receptor expressing BA/F3 cells. After a 48h culture period a 3 H thymidine pulse was carried out and the incorporated radioactivity determined. E2 F2 G2 I2 J2 K2 L2 M2 N2 O2 Q2 R2 S2 T2 U2 V2   Detector antibody   Coating antibody   A2  D2  E2  F2  G2  I2  J2  K2  L2  M2  N2  O2  Q2  R2  S2  T2  U2  V2 A. 
